Press Release

CD BIOPARTICLES ANNOUNCES CARRAGEENANS FOR SCIENTIFIC APPLICATIONS



CD Bioparticles has recently announced the launch of its Carrageenans for various applications such as drug delivery, food, and cosmetics.

FOR IMMEDIATE RELEASE

19/05/2023

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently announced the launch of its Carrageenans for various applications such as drug delivery, food, and cosmetics.

Carrageenan (CG) is a sulfated linear polysaccharide composed of D-galactose and 3,6-anhydro-D-galactose derived from certain red seaweeds of the Rhodophyceae family, e.g. Agardhiella, Chondrus crispus, Eucheuma, Furcellaria, Gigartina, Hypnea, Iridaea, Sarconema, and Solieria.

The use of carrageenan was first described in Ireland in the early 19th century. In recent years, carrageenan-based biomaterials have received considerable attention due to their versatility, including biodegradability, biocompatibility and non-toxicity, as well as their bioactive properties, such as antiviral, antibacterial, antihyperlipidemic, anticoagulant, antioxidant, antitumor and immunomodulatory properties. They have been utilized in pharmaceutical formulations because their bioactive and physicochemical properties make them suitable biomaterials for drug delivery and, more recently, for the development of tissue engineering.

CD Bioparticles now offers a range of carrageenans, such as alfa-Carrageenan, iota-Carrageenan, Type II, and kappa-Carrageenan for drug delivery and pharmaceutical researchers. In addition, as a supplier of biocompatible drug delivery systems, CD Bioparticles also supplies various biodegradable polymers for research usage, such as Dextrans, Chitosans, Heparins, and Dendrimers, enabling scientists to overcome challenges, e.g., uncontrollable drug delivery profiles, limited ability to bioconjugate between macromolecules and biomolecules, unpredictable or uncontrolled degradation rates of drug-loaded cargos, tedious chemical synthesis and purification, and denaturation of biomolecules during the conjugation.

Features

Extensive coverage of biomaterials with different physical properties such as Tg, Tm, shear viscosity, Young's modulus, and dielectric constant to meet individual biomaterial processing conditions and end-product requirements.
Various functionalized biomolecules to facilitate custom conjugation, modification, and crosslinking applications.
Precise formulation of polymer composition and controlled degradation time for various drug delivery and biografting applications.
Effective conjugation reactions at ambient conditions to prevent protein denaturation.
Temperature-dependent solubility of biomaterials in aqueous solutions with controlled transition temperatures, such as different UCST and LCST.

"We're committed to providing our customers with the highest quality technology and service to help them achieve the most reliable experimental results. As carrageenan continues to advance in laboratory testing and practical processing, we'll assist researchers in unlocking the full value and potential of this biodegradable polymer." said Robin J. Watts, Ph.D., the scientific director of research and development at CD Bioparticles. "We're confident that our continued support of researchers and their projects will accelerate their research process and help them make additional pharmaceutical advances."

For more information about carrageenans or other transfection products, please visit CD Bioparticles at https://www.cd-bioparticles.net/.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Tags:
CD Bioparticles  |  Carrageenans  |  

---

Organisation Profile:
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems.






Press release contact details for CD Bioparticles

NameCD Bioparticles
Tel1-631-346-0027
Fax
Email
Websitehttps://www.cd-bioparticles.net/
OrganisationCD Bioparticles
Address
Town
County0
Postcode




Other press releases from CD Bioparticles

CD Bioparticles Launches Gene Silencing for Bio-research Application
CD Bioparticles Launches Gel Permeation Chromatography Resins
CD Bioparticles Introduces Reversed Phase Chromatography Resins for Biological Analysis
CD Bioparticles Launches mRNA Transfection Reagents for Research Applications
CD Bioparticles Launches Normal Phase Chromatography Resins for Chromatographic Analysis
CD Bioparticles Launches 3D Transfection Reagents for Bio-research Applications
CD Bioparticles Launches Affinity Chromatography Resins for Laboratory Usage
CD Bioparticles Announces Carrageenans for Scientific Applications
CD Bioparticles Launches New Chromatography Resins for Improved Analysis and Preparation of Chiral Compounds
CD Bioparticles Launches New Alginic Acids for Research Applications
CD Bioparticles Launches Locust Bean Gum for Biopharmaceutical Applications
CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications
CD Bioparticles Launches New Line of Bioinks for 3D Bioprinting
CD Bioparticles Launches New Quantum Dots Labeling & Conjugation Kits
CD Bioparticles Introduces New Extraction and Purification Kits for Rapid and Reliable DNA Isolation
CD Bioparticles Launches New Tissue Engineering Scaffolds for Researchers
CD Bioparticles Launches New Line of Polystyrene Particles Conjugated with Biomolecules
CD Bioparticles Launches 3D Cell Culture Substrate for Bio-research
CD Bioparticles Announces the Launch of New Flow Cytometry Particles
CD Bioparticles Introduces the Launch of Engineered Tissue Scaffolds
CD Bioparticles Announces Polyamino Acids for Drug Delivery Applications
CD Bioparticles Launches New Line of Functional Polystyrene Particles
CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research
CD Bioparticles Unveils Versatile Plain Polystyrene Particles for Diverse Bioresearch Applications
CD Bioparticles Launches New Range of Low PDI Polymers for Drug Delivery Applications
CD Bioparticles Launches New Line of Particles for Solid Phase Organic Synthesis
CD Bioparticles Introduces Innovative Agarose Particles for Purification of Proteins and Antibodies
CD Bioparticles Announces New Line of Polyacrylamides for Drug Delivery Studies
CD Bioparticles Announces Versatile Basic Agarose Particles for Efficient Biomolecule Separation
CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications
CD Bioparticles Announces New Line of Conjugated Agarose Particles for Affinity Separation and Purification
CD Bioparticles Announces Offering of Polystyrene Family Polymers for Drug Delivery
CD Bioparticles Announces Comprehensive Assay Portfolio for mRNA-LNP Vaccine Development
CD Bioparticles Introduces Functional Agarose Particles for Biomedical Research Applications
CD Bioparticles Announces Advanced Capabilities in Customized Liposomes for Targeted Delivery
CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.